Clinical trial · Interventional
Phase II Trial of RAD001 in Refractory Colorectal Cancer
Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer
NCT00337545CI-TRIAL-00000910completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RAD001 | Drug | Everolimus | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens * Measurable disease * ECOG 0-2 Exclusion Criteria: * CNS disease * Chemotherapy or radiotherapy \< 4 weeks prior * Active bleeding diathesis
References
Publications (0)
Data not yet available
No reference posted for this study.